Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 3/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 6/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | KIT | P10721 | 4/20 | 0.38 |
| ▸ | ABL2 | P42684 | 4/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752954 | 0.87 | ALDH1A1 (0.46) | TGFBR1ACVR1CHKATNIKABL1 | |
| SCHEMBL2239545 | 0.85 | TGFBR1 (0.41) | TGFBR1ACVR1CHKATNIKABL1 | |
| SCHEMBL27827758 | 0.84 | TGFBR1 (0.41) | TGFBR1ACVR1CHKATNIKABL1 | |
| SCHEMBL4158945 | 0.78 | MAP3K11 (0.47) | TGFBR1TNIKABL1SRCSYK | |
| SCHEMBL2238789 | 0.77 | CYP2D6 (0.41) | TGFBR1 | |
| SCHEMBL2240380 | 0.77 | GSK3B (0.40) | ABL1KITABL2PDGFRBBCR | |
| SCHEMBL3720028 | 0.75 | GSK3B (0.42) | TGFBR1ACVR1CHKATNIKABL1 | |
| SCHEMBL2305188 | 0.72 | TNIK (0.44) | CHKATNIKABL1KITABL2 | |
| SCHEMBL3727999 | 0.71 | PIK3CD (0.40) | ACVR1 | |
| SCHEMBL13046876 | 0.71 | HDAC1 (0.42) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | claimed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | claimed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | TGFBR1 478/4885ACVR1 202/4885CHKA 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.